JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs

Abstract

BackgroundMicrosomal transfer protein inhibitors (MTPi) have the potential to be used as a drug to lower plasma lipids, mainly plasma triglycerides (TG). However, studies with animal models have indicated that MTPi treatment results in the accumulation of hepatic TG. The purpose of this study was to evaluate whether JTT-130, a unique MTPi, targeted to the intestine, would effectively reduce plasma lipids without inducing a fatty liver.MethodsMale guinea pigs (n = 10 per group) were used for this experiment. Initially all guinea pigs were fed a hypercholesterolemic diet containing 0.08 g/100 g dietary cholesterol for 3 wk. After this period, animals were randomly assigned to diets containing 0 (control), 0.0005 or 0.0015 g/100 g of MTPi for 4 wk. A diet containing 0.05 g/100 g of atorvastatin, an HMG-CoA reductase inhibitor was used as the positive control. At the end of the 7th week, guinea pigs were sacrificed to assess drug effects on plasma and hepatic lipids, composition of LDL and VLDL, hepatic cholesterol and lipoprotein metabolism.ResultsPlasma LDL cholesterol and TG were 25 and 30% lower in guinea pigs treated with MTPi compared to controls (P < 0.05). Atorvastatin had the most pronounced hypolipidemic effects with a 35% reduction in LDL cholesterol and 40% reduction in TG. JTT-130 did not induce hepatic lipid accumulation compared to controls. Cholesteryl ester transfer protein (CETP) activity was reduced in a dose dependent manner by increasing doses of MTPi and guinea pigs treated with atorvastatin had the lowest CETP activity (P < 0.01). In addition the number of molecules of cholesteryl ester in LDL and LDL diameter were lower in guinea pigs treated with atorvastatin. In contrast, hepatic enzymes involved in maintaining cholesterol homeostasis were not affected by drug treatment.ConclusionThese results suggest that JTT-130 could have potential clinical applications due to its plasma lipid lowering effects with no alterations in hepatic lipid concentrations.

Disturbed Chylomicron Metabolism in Type 2 Diabetes - A Preventable Cause of Atherosclerosis?

“…Intestinal MTP has become a hot topic since new inhibitors of intestinal MTP have been shown to lower triglyceride without causing hepatic steatosis at least in animal studies [84,85]. Although many polymorphisms of MTP have been described, some of which have considerable impact on LDL cholesterol in both non-diabetic and diabetic subjects [86,87], it is difficult to know whether the results mainly stemmed from the effect in the liver rather than the intestine.…”

Animal models for the atherosclerosis research: a review

“…Further, significant atherogenic inflammation with an increase in aortic cytokines has been documented in guinea pigs. The mechanisms of certain drugs affecting triglyceride metabolism can also be explored (Aggarwal et al, 2005;Aggarwal et al, 2006). However, no advanced atherosclerotic lesions have been observed in guinea pigs (Lynch et al, 1996;Singh et al, 2009), and the literature considering guinea pigs as surrogates to surgical models is quite sparse.…”

Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future

“…Patients must be kept on a low lipid diet to limit severe diarrhoea symptoms, while in clinical trials liver damage accompanied by liver steatosis was observed (29). Other compounds of this class currently being tested specifically target MTP in the intestines to avoid hepatotoxicity (30,31). Mipomersen is an ASO drug inhibiting the synthesis of ApoB-100, a major constituent of LDL particles, at the mRNA level (32).…”